Sonia Hallen joined Gilde Healthcare in 2024 as an Investment Manager. She focuses on venture and growth capital investments in therapeutic and healthtech sectors.
Prior to Gilde, Sonia was a Vice President at EQT Life Sciences (and formerly LSP) dedicated to the firm’s flagship therapeutics-focused venture funds. She held board positions on Evommune, ViCentra, and NOBI, and was heavily involved in numerous investments in private therapeutics and medtech companies. Prior to EQT, Sonia founded two start-ups, focused in digital health and infectious disease diagnostics. Before her entrepreneurial work, she was a strategy consultant within Accenture’s life sciences practice, based in the London office.
Sonia holds a BEng in Chemical Engineering from McGill University and an MSc in Biotechnology from the Swiss Federal Institute of Technology Lausanne (EPFL). She completed her PhD with Dame Molly Stevens at Imperial College London, where she developed induced pluripotent stem (iPS) cell-based regenerative medicines.
She is a citizen of Canada and the Czech Republic, based in Gilde’s Utrecht office.
